<?xml version='1.0' encoding='utf-8'?>
<document id="15624117"><sentence text="Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier." /><sentence text="The distribution of the antidepressant drug nortriptyline (NT) and its main metabolite E-10-hydroxy-nortriptyline (E-10-OH-NT) across the blood-brain barrier was considered in relation to inhibition of the multidrug transporter P-glycoprotein (P-gp)"><entity charOffset="44-57" id="DDI-PubMed.15624117.s2.e0" text="nortriptyline" /><entity charOffset="59-61" id="DDI-PubMed.15624117.s2.e1" text="NT" /><entity charOffset="87-113" id="DDI-PubMed.15624117.s2.e2" text="E-10-hydroxy-nortriptyline" /><entity charOffset="115-125" id="DDI-PubMed.15624117.s2.e3" text="E-10-OH-NT" /><entity charOffset="123-132" id="DDI-PubMed.15624117.s2.e4" text="NT" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e0" e2="DDI-PubMed.15624117.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e0" e2="DDI-PubMed.15624117.s2.e1" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e0" e2="DDI-PubMed.15624117.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e0" e2="DDI-PubMed.15624117.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e0" e2="DDI-PubMed.15624117.s2.e4" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e1" e2="DDI-PubMed.15624117.s2.e1" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e1" e2="DDI-PubMed.15624117.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e1" e2="DDI-PubMed.15624117.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e1" e2="DDI-PubMed.15624117.s2.e4" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e2" e2="DDI-PubMed.15624117.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e2" e2="DDI-PubMed.15624117.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e2" e2="DDI-PubMed.15624117.s2.e4" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e3" e2="DDI-PubMed.15624117.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15624117.s2.e3" e2="DDI-PubMed.15624117.s2.e4" /></sentence><sentence text=" Rats received NT in doses of 25 mg/kg orally, 10 mg/kg i"><entity charOffset="15-17" id="DDI-PubMed.15624117.s3.e0" text="NT" /></sentence><sentence text="p" /><sentence text=" or 25 mg/kg i" /><sentence text="p" /><sentence text=" Half the rats were treated with the P-glycoprotein inhibitor cyclosporine A (CsA) (200 mg/kg) 2 h prior to NT administration, and the other half served as a control group"><entity charOffset="62-76" id="DDI-PubMed.15624117.s7.e0" text="cyclosporine A" /><entity charOffset="78-81" id="DDI-PubMed.15624117.s7.e1" text="CsA" /><entity charOffset="108-110" id="DDI-PubMed.15624117.s7.e2" text="NT" /><pair ddi="false" e1="DDI-PubMed.15624117.s7.e0" e2="DDI-PubMed.15624117.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15624117.s7.e0" e2="DDI-PubMed.15624117.s7.e1" /><pair ddi="false" e1="DDI-PubMed.15624117.s7.e0" e2="DDI-PubMed.15624117.s7.e2" /><pair ddi="false" e1="DDI-PubMed.15624117.s7.e1" e2="DDI-PubMed.15624117.s7.e1" /><pair ddi="false" e1="DDI-PubMed.15624117.s7.e1" e2="DDI-PubMed.15624117.s7.e2" /></sentence><sentence text=" NT and the metabolite were extracted from brain and serum by liquid-liquid extraction and analysed by HPLC with UV-detection"><entity charOffset="1-2" id="DDI-PubMed.15624117.s8.e0" text="NT" /></sentence><sentence text=" The brain to serum ratio of NT was increased in the CsA treated groups (22"><entity charOffset="29-30" id="DDI-PubMed.15624117.s9.e0" text="NT" /><entity charOffset="53-54" id="DDI-PubMed.15624117.s9.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.15624117.s9.e0" e2="DDI-PubMed.15624117.s9.e0" /><pair ddi="false" e1="DDI-PubMed.15624117.s9.e0" e2="DDI-PubMed.15624117.s9.e1" /></sentence><sentence text="3-26" /><sentence text="8) compared with the control groups (16" /><sentence text="5-22" /><sentence text="7), the difference being statistically significant in two of the three experiments (p&lt;0" /><sentence text="05)" /><sentence text=" Increased brain-serum ratios were also found for E-10-OH-NT, but the differences were not statistically significant"><entity charOffset="50-60" id="DDI-PubMed.15624117.s15.e0" text="E-10-OH-NT" /><entity charOffset="58-67" id="DDI-PubMed.15624117.s15.e1" text="NT" /><pair ddi="false" e1="DDI-PubMed.15624117.s15.e0" e2="DDI-PubMed.15624117.s15.e0" /><pair ddi="false" e1="DDI-PubMed.15624117.s15.e0" e2="DDI-PubMed.15624117.s15.e1" /></sentence><sentence text=" These results suggest that inhibition of P-gp by CsA increases the accumulation of NT in the brain"><entity charOffset="84-85" id="DDI-PubMed.15624117.s16.e0" text="NT" /><entity charOffset="50-51" id="DDI-PubMed.15624117.s16.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.15624117.s16.e1" e2="DDI-PubMed.15624117.s16.e1" /><pair ddi="false" e1="DDI-PubMed.15624117.s16.e1" e2="DDI-PubMed.15624117.s16.e0" /></sentence><sentence text=" Administration of the antipsychotic drug risperidone (0"><entity charOffset="42-53" id="DDI-PubMed.15624117.s17.e0" text="risperidone" /></sentence><sentence text="5 mg/kg s" /><sentence text="c" /><sentence text="), which is a P-gp substrate, instead of CsA did not exert any measurable influence on the blood-brain ratio of NT concentrations"><entity charOffset="112-122" id="DDI-PubMed.15624117.s20.e0" text="NT" /><entity charOffset="41-51" id="DDI-PubMed.15624117.s20.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.15624117.s20.e1" e2="DDI-PubMed.15624117.s20.e1" /><pair ddi="false" e1="DDI-PubMed.15624117.s20.e1" e2="DDI-PubMed.15624117.s20.e0" /></sentence><sentence text=" In conclusion, the results show that drug-drug interaction at P-gp may influence the intracerebral NT concentration, but apparently, a major inhibition of P-gp is necessary to attain a measurable effect"><entity charOffset="100-102" id="DDI-PubMed.15624117.s21.e0" text="NT" /></sentence><sentence text="" /></document>